MeiraGTx Holdings PLC MGTX:NASDAQ

Last Price$8.46NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/17/22

Today's Change-0.02(0.24%)
Bid (Size)$8.44 (9)
Ask (Size)$15.10 (5)
Day Low / High$8.28 - 8.84
Volume134.9 K
 

View Biotechnology IndustryPeer Comparison as of 05/17/2022

 

MeiraGTx Holdings PLC ( NASDAQ )

Price: $8.46
Change: -0.02 (0.24%)
Volume: 134.9 K
4:00PM ET 5/17/2022
 
 

PolarityTE Inc ( NASDAQ )

Price: $2.97
Change: -103.65 (97.21%)
Volume: 612.0 K
4:00PM ET 5/17/2022
 
 

ADMA Biologics Inc ( NASDAQ )

Price: $2.02
Change: +0.15 (8.02%)
Volume: 3.2 M
4:00PM ET 5/17/2022
 
 

Kezar Life Sciences Inc ( NASDAQ )

Price: $6.63
Change: +0.61 (10.13%)
Volume: 1.3 M
4:00PM ET 5/17/2022
 
 

Heron Therapeutics Inc ( NASDAQ )

Price: $3.79
Change: +0.25 (7.06%)
Volume: 2.2 M
4:00PM ET 5/17/2022
 

Read more news Recent News

--Chardan Lowers MeiraGTx Holdings's Price Target to $46 From $55, Maintains Buy Rating
10:47AM ET 5/13/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Barclays Lowers MeiraGTx Holdings's Price Target to $18 From $32, Maintains Overweight Rating
10:47AM ET 5/13/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Piper Sandler Adjusts MeiraGTx Holdings' Price Target to $30 From $40, Reiterates Overweight Rating
5:06AM ET 5/13/2022 MT Newswires

MeiraGTx Holdings (MGTX) has an average rating of buy and price targets ranging from $18 to $55, according to analysts polled by Capital IQ. (MT Newswires...

MeiraGTx Holdings 2021 Net Loss Widens; Expects Sufficient Capital Through Q2 2023
8:41AM ET 3/10/2022 MT Newswires

MeiraGTx Holdings (MGTX) on Thursday reported a full-year 2021 net loss of $1.80 per diluted share, widening from a loss of $1.54 per share in 2020....

View all Commentary and Analysis

Corporate Presentation March 2022
5:53PM ET 4/29/2022 Seeking Alpha

MeiraGTx: Perceptive's Large Stake Makes It Interesting
9:40PM ET 1/18/2022 Seeking Alpha

MeiraGTx: Novel Riboswitch Technology Could Add Value
3:44PM ET 11/01/2021 Seeking Alpha

Wall Street Breakfast: What Moved Markets
8:23AM ET 10/23/2021 Seeking Alpha

Company Profile

Business DescriptionMeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY. View company web site for more details
Address430 East 29th Street
New York, New York 10016
Phone+1.646.860.7985
Number of Employees68
Recent SEC Filing05/12/20228-K
President, Chief Executive Officer & DirectorAlexandria Forbes
Chief Operating & Financial OfficerRichard Giroux
Chief Medical OfficerRobert K. Zeldin
Chief Development OfficerStuart Naylor

Company Highlights

Price Open$8.60
Previous Close$8.48
52 Week Range$8.25 - 24.89
Market Capitalization$378.2 M
Shares Outstanding44.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.80
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-211.03%
Return on Equity-39.79%

Analyst Ratings as of 05/12/2022

Buy
6
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset